Anti-VEGF Eye Implant Preserves Vision in Diabetic Macular Edema for 4 Years

Diabetic macular edema is a leading cause of vision loss among people with diabetes, and it typically requires frequent eye injections to manage. A continuous-delivery implant called the ranibizumab port delivery system (PDS), marketed as Susvimo, may represent a major leap forward in how this condition is treated.

The PAGODA trial followed patients for 208 weeks — roughly four years — and found that those using the PDS achieved an average improvement of 9.4 letters in best corrected visual acuity and a 211-micron reduction in central retinal thickness. These gains were sustained long-term. Patients who initially received monthly injections but switched to the PDS at 64 weeks achieved similar outcomes, suggesting the device can rescue and maintain vision even after delayed adoption.

A standout finding was the dramatic reduction in treatment burden. During PDS use, 95% of patients required no supplemental anti-VEGF therapy between their 6-month device refills. Approximately 75% of all patients regained driving-level vision — a meaningful quality-of-life threshold for a predominantly working-age population.

Beyond efficacy, researchers highlighted a significant pharmacological insight: the biologic drug stored inside the device remained active at body temperature for over a year. This challenges assumptions about biological drug stability and could have implications for drug delivery research broadly.

Safety signals were manageable and consistent with prior data, with no new concerns emerging during extended follow-up. Patient surveys showed 80–90% preferred the PDS over more frequent injections. Physicians noted that patients who travel frequently or require intensive injection schedules are ideal candidates. While the PDS is not a cure for diabetic eye disease, it represents a meaningful step toward reducing the treatment burden that leads many patients to delay or discontinue care.